Literature DB >> 19758310

Effects of Sp1 overexpression on cultured human corneal stromal cells.

Xiang Shen1, Jeong-Seok Park, Ye Qiu, Joel Sugar, Beatrice Y J T Yue.   

Abstract

Sp1, a transcription factor, is upregulated in keratoconus, a cornea-thinning disease. Keratoconus corneas have also been shown to contain increased levels of degradative enzymes such as cathepsin B and decreased proteinase inhibitors such as alpha1-proteinase inhibitor (alpha1-PI). We transfected cultured human corneal stromal cells to overexpress Sp1. The resulting effects on cathepsin B and alpha1-PI levels as well as the cellular proliferative and apoptotic activities were examined by Western blotting and cytochemical staining. It was found that the Sp1 transfected cells contained a greater amount of cathepsin B than did mock transfected controls. The activity of cathepsin B was also increased. By contrast, the protein level of alpha1-PI was lowered in corneal stromal cells upon Sp1 overexpression. The Sp1-induced alterations thus mimicked closely those observed in keratoconus, supporting the notion that Sp1 upregulation may be a key factor contributing directly to the disease development. Furthermore, the apoptotic activity was unaffected in Sp1 transfectants but the proliferation was inhibited, consistent with the idea that Sp1 may play a role in differentiation of corneal cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758310      PMCID: PMC2813039          DOI: 10.1111/j.1365-2443.2009.01340.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  36 in total

1.  Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation.

Authors:  Mary M Kavurma; Levon M Khachigian
Journal:  J Biol Chem       Date:  2003-06-09       Impact factor: 5.157

Review 2.  The genetics of keratoconus.

Authors:  Yaron S Rabinowitz
Journal:  Ophthalmol Clin North Am       Date:  2003-12

3.  Involvement of corneal nerves in the progression of keratoconus.

Authors:  N H Brookes; I-P Loh; G M Clover; C A Poole; T Sherwin
Journal:  Exp Eye Res       Date:  2003-10       Impact factor: 3.467

Review 4.  Gene regulation by Sp1 and Sp3.

Authors:  Lin Li; Shihua He; Jian-Min Sun; James R Davie
Journal:  Biochem Cell Biol       Date:  2004-08       Impact factor: 3.626

5.  Alpha-1 proteinase inhibitor levels in keratoconus.

Authors:  S Sawaguchi; S S Twining; B Y Yue; P M Wilson; J Sugar; S K Chan
Journal:  Exp Eye Res       Date:  1990-05       Impact factor: 3.467

Review 6.  Keratoconus and related noninflammatory corneal thinning disorders.

Authors:  J H Krachmer; R S Feder; M W Belin
Journal:  Surv Ophthalmol       Date:  1984 Jan-Feb       Impact factor: 6.048

7.  Studies of corneas in vivo and in vitro.

Authors:  B Y Yue; J L Baum
Journal:  Vision Res       Date:  1981       Impact factor: 1.886

8.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues.

Authors:  M R Buck; D G Karustis; N A Day; K V Honn; B F Sloane
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

9.  Keratocyte phenotype mediates proteoglycan structure: a role for fibroblasts in corneal fibrosis.

Authors:  James L Funderburgh; Mary M Mann; Martha L Funderburgh
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

10.  Difference between the glycosaminoglycans synthetized by corneal and cutaneous fibroblasts in culture.

Authors:  G K Klintworth; C F Smith
Journal:  Lab Invest       Date:  1981-06       Impact factor: 5.662

View more
  2 in total

1.  Ocular surface development and gene expression.

Authors:  Shivalingappa K Swamynathan
Journal:  J Ophthalmol       Date:  2013-02-21       Impact factor: 1.909

2.  A Novel Interaction between TFII-I and Mdm2 with a Negative Effect on TFII-I Transcriptional Activity.

Authors:  Kateřina Cetkovská; Hana Šustová; Pavlína Kosztyu; Stjepan Uldrijan
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.